For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Alliance A031704

Trial Overview

Official Title

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab with Cabozantinib for Patients with Advanced Kidney Cancer

Study Purpose

To see how well nivolumab and ipilimumab, followed by nivolumab versus cabozantinib and nivolumab, work in treating renal cell cancer that is untreated and has spread to other parts of the body.

Diagnosis

Metastatic untreated Renal Cell Carcinoma

Eligibility

Renal Cell Carcinoma with clear cell component

Measureable disease

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

Treatment with ipilimumab and nivolumab every 3 weeks for 4 treatments (lasting about 12 weeks). Then, based on scan results, patients will be treated with either nivolumab or cabozantinib, or nivolumab and cabozantinib for up to 1 year.

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Phase
Phase III
Methodist Health System Trial Code
A031704
Related Specialties